VBL Therapeutics Reverse Merged with Notable Labs to Advance Predictive Precision Medicines Platform and Therapeutic Pipeline
- Notable stockholders will receive newly issued ordinary shares & investors have committed an additional $10.3M in a private placement to Notable, led by Builders VC, B Capital Group, Y Combinator, First Round Capital & Founders Fund. The merger is expected to be close in Q2’23
- The combined company will advance Notable’s PPMP & therapeutic pipeline incl. volasertib for cancer patients. Notable's PPMP combines biological assays & ML for the purpose of bio-simulating a patient's cancer treatment and predicting their clinical response to actual treatment, P-IIa results of Volasertib are expected in Q3’24 for AML
- Notable stockholders will own ~76% & VBL shareholders will hold ~24% of the combined company. The combined company is expected to operate under the name Notable Labs, Ltd. with its shares listed on the Nasdaq under the ticker symbol ‘NTBL
Ref: GlobeNewswire | Image: VBL Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.